



TRANSPARENCY AND ACCESS TO MEDICINES: ONE YEAR AFTER THE WHA RESOLUTION

21 MAY 2020 | 15:00 – 16:30

73rd World Health Assembly Week

BIOGRAPHIES OF SPEAKERS

More information: graduateinstitute.ch/73WHA-Transparency

LENIAS HWENDA

Co-Chair, WHA 72.8 Transparency Resolution Negotiations



Lenias Hwenda is a health entrepreneur, and a medicines procurement and supply chain expert passionate about improving the availability of quality medical products at prices that are not a barrier to access by patients. She is the founder and the CEO of Medicines for Africa, a social enterprise that provides high-impact medicines services to buyers of medicines in African countries. Lenias is an influential African thought leader who over the past decade has made significant contributions to global policy discussions on what is needed to improve access to medical products by the most vulnerable people in the world. She recently

co-chaired high-level landmark global negotiations on improving the transparency of markets for medicines, vaccines, and other health products amongst WHO Member States in Geneva.

LUCA LI BASSI

Former AIFA General Director; Co-Chair, WHA 72.8 Transparency Resolution Negotiations



Luca Li Bassi is a medical doctor by training who has worked for 25 years of public health and health management experience across Australasia, Europe and Africa. He occupied different positions both in the private and the public sector, successfully working for national governments, bilateral and multilateral organisations, NGO's and research and academic institutions. He served at the Pharmaceutical Management Agency in New Zealand, the Global Fund to Fight AIDS, tuberculosis and Malaria, the International Atomic Energy Agency and more recently

as Director General of the Italian Medicines Agency. Former Director General of the Italian medicines agency (AIFA), he led the negotiations of the milestone resolution on "Improving the transparency of markets for medicines, vaccines, and other health products", during the 72nd World Health Assembly in May 2019. He has contributed to drafting the decree to improve transparency in Italy, which has already been signed by the Health and Finance Ministers, and only needs to be published on the official National Gazette. It will make Italy one of the first countries to implement the resolution that the country introduced at the 72nd WHA with several other "co-sponsor" countries.

CAROLINE FIAT

Member of French Parliament, Co-Author of Amendments on Transparency in Medicines Policies, Paris



Caroline Fiat is a Member of Parliament from Meurthe et Moselle constituency since 2017. She is part of the Political group La France insoumise, and also a member of the group “Gauche Républicaine et Socialiste” and formerly a member of the French communist party. Before being elected she was working at night in EHPAD (accommodation facility for dependent elderly people). First nursing assistant to become a Member of Parliament, she is a member of the social affairs commission. Her fights are mainly on health issues, either within the Parliament or in her constituency, as shows her numerous speeches and her Parliamentary report regarding the situation in accommodation facilities for dependent elderly people, for psychiatry, for State Medical Aid, regarding the sanitary scandal of Depakine, as well as her law proposal on euthanasia. Member of Parliament (MP) representing La France Insoumise, she defended, jointly with other MPs and Senators amendments on transparency within the scope of the Bill on Social Security Funding for 2020, including one of her amendment on R&D public funding that was adopted. The amendment was co-drafted with La République en Marche (the majority party at the National Assembly), and Olivier Véran the general rapporteur of the bill (and current Minister of health), while Caroline Fiat is a member of an opposed political party, showing that the transparency issue is a critical topic that goes beyond political divisions. Caroline Fiat has continued this fight after the Constitutional Council has censored the amendment in December 2019. The fight around these amendments, within the scope of this bill and the adoption of one of them is a so-far unprecedented example in the world of the implementation of the 72nd WHA resolution within the legislative framework in a country.

MUSTAQUEEM DE GAMA


Counsellor, South African Permanent Mission to the WTO



Mustaqeem De Gama is currently a Counsellor with the South African Mission in Geneva and accredited to the WTO and UN. He covers rules disciplines, DSB, TRIPS and TRIMS. He previously worked at the Department of Trade and Industry in South Africa and headed the Legal International Trade and Investment Directorate.

PAUL FEHLNER

President and CEO, reVision Therapeutics, Inc.



Paul Fehlner is Co-Founder and President/CEO of reVision Therapeutics, Inc. (www.revisiontx.com), which was created to advance low price innovative medicines. Concurrently, he is Chief Intellectual Property Officer at Axcella Health, a clinical stage company in Cambridge, Massachusetts and a Principal of Life Sciences Innovation LLC, a consulting company that advises on products and technologies and provides BD&L support in life sciences. Previously, he was Head of Intellectual Property for Novartis Pharma in Basel, Switzerland, leading a team of over 120 colleagues in 5 countries to obtain, maintain, and enforce IP rights for the company in collaboration with global and local stakeholders. He joined Novartis in 2008 from the international law firm Baker Botts, where he led the firm's life sciences IP practice. He was an associate and partner at Darby & Darby, Biotechnology Counsel for Rhône-Poulenc Rorer, an associate at Klauber & Jackson, and began his career in 1990 at Pennie & Edmonds. He has a JD from Fordham, a PhD from Rockefeller University (Lois P Markey Fellow), and a BS from Haverford College (high honours; Phi Beta Kappa).

MODERATORS

PAULINE LONDEIX

Co-Founder, OTMeds; Access to Medicines Advocate, Researcher, Writer and Film-Maker



Pauline is the co-founder of the Observatory on transparency on medicines policies (OTMeds). OTMeds proposed amendments on transparency to Members of the French Parliament in 2019, including one on transparency of the public funding to R&D that was adopted by the Parliament. She is a former Act Up-Paris vice-president and has been a consultant for many non-governmental organisations since 2012, most of them based in developing countries. Pauline has worked on access to treatments, mainly on HIV/AIDS, hepatitis C, tuberculosis, diabetes, but also on diagnostics (on which she authored several reports). She is board member of Sidaction (Paris, France), plenary member of the international review board (IRB) of the Pasteur institute (Paris, France), member of the Global community advisory board on tuberculosis (TB-CAB), and member of the Conseil national de la nouvelle résistance (CNNR).

SUERIE MOON

Co-Director, Global Health Centre; Visiting Lecturer, Graduate Institute, Geneva



Suerie Moon, MPA, PhD, is Co-Director of the Global Health Centre and Visiting Lecturer at the Graduate Institute of International and Development Studies, Geneva. She also teaches and advises doctoral students at the Harvard T.H. Chan School of Public Health as Adjunct Lecturer on Global Health. Her research and teaching focus on global governance, the political economy of global health (focusing on innovation and access to medicines; outbreak preparedness and response; trade, investment and intellectual property rules; and development assistance for health), the evolution of international regimes, and innovative policies for addressing global problems. She is the author, with Wolfgang Hein, of *Informal Norms in Global Governance: Human Rights, Intellectual Property Rules, and Access to Medicines* (Routledge, 2013). She has conducted research on the policies and politics shaping innovation and access to medicines for twenty years, starting at Médecins Sans Frontières in 1999. She has served on a number of expert advisory bodies, including most recently the Board of Directors of the Drugs for Neglected Diseases initiative, WHO Fair Pricing Forum Advisory Group, Expert Advisory Group to the UN Secretary General's High-Level Panel on Access to Medicines, Proposal Review Committee of UNITAID, and US National Academies of Medicine Forum on Antimicrobial Threats. Prior to joining the Graduate Institute, she was Study Director of the Harvard-LSHTM Independent Panel on the Global Response to Ebola, and co-founded and led the Forum on Global Governance for Health, a focal point at Harvard University for research, debate and strategic convening on issues at the intersection of global governance and health. She received a BA from Yale, an MPA from Princeton, and PhD from the Harvard Kennedy School of Government.